Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07380711 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes

Study acronym: AURORA
StatusRecruiting
PhaseNot specified
SponsorSanofi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 2 of 21 entries
    • Trial sites expanded: 22 → 28 locations
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 1 of 13 entries
  2. Study sites: 20 to 22v5
  3. Study sites: 9 to 20v4
  4. Eligibility criteria expanded, about 20 words
    • Primary endpoints revised (21)
    v3
  5. Study sites: 2 to 9
    • Start date changed from estimate of Feb 10, 2026 to Jan 28, 2026
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sanofi
284 trials monitored
See 12 trials at risk
COPD
1,119 trials monitored
See 34 trials at risk
The OBS19236 is a retrospective and prospective, non-interventional observational study in COPD patients treated with dupilumab as part of routine clinical care. It will follow-up about 350 to 500 participants over 36 months in up to 50 sites in France.
Trial Details
NCT Number NCT07380711
Lead Sponsor Sanofi
Conditions
(from sponsor)		 Chronic Obstructive Pulmonary Disease COPD
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov